Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Sheba Medical Center · University of California, Los Angeles · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,230
total citations
- FWCI
- 66.98
- Percentile
- 100%
- References
- 33
Citations per year
Authors
20- JSJacob SchachterCorresponding
Sheba Medical Center
- ARAntoni Ribas
University of California, Los Angeles
- GVGeorgina V. Long
The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia
- AAAna Arance
Hospital Clínic de Barcelona
- JGJean‐Jacques Grob
Aix-Marseille Université, Hôpital de la Timone
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Ipilimumab
- Medicine
- Open label
- Oncology
- Open label study
- Internal medicine
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.